Compare · MBX vs NVO
MBX vs NVO
Side-by-side comparison of MBX Biosciences Inc. (MBX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MBX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $218.21B, about 76.4x MBX ($2.86B).
- Over the past year, MBX is up 332.7% and NVO is down 28.5% - MBX leads by 361.2 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 4 for MBX).
- NVO has more recent analyst coverage (25 ratings vs 12 for MBX).
- Company
- MBX Biosciences Inc.
- Novo Nordisk A/S
- Price
- $60.01-1.62%
- $49.28-0.40%
- Market cap
- $2.86B
- $218.21B
- 1M return
- +93.52%
- +15.17%
- 1Y return
- +332.66%
- -28.54%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 4
- 5
- Recent ratings
- 12
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MBX
- SEC Form 8-K filed by MBX Biosciences Inc.
- MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
- Amendment: SEC Form SCHEDULE 13G/A filed by MBX Biosciences Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by MBX Biosciences Inc.
- MBX Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
- SEC Form 144 filed by MBX Biosciences Inc.
- SEC Form 144 filed by MBX Biosciences Inc.
- SEC Form 4 filed by Director Mathers Edward T
- SEC Form 4 filed by Director Pescovitz Ora H.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S